Search clinical trials for: Lu AA34893

Total 290 results

H. Lundbeck A/S

Recruiting

A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants

Healthy Participants

Netherlands
University of Wisconsin, Madison

Not yet recruiting

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Neuroendocrine Tumors | Somatostatin Receptor-positive Neuroendocrine Tumor

United States
University of Chicago

Recruiting

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Pancreas Cancer | Pancreatic Neuroendocrine Tumor

United States
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
University of California, San Francisco
National Cancer Institute (NCI); Prostate Cancer Foundation

Active, not recruiting

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer

United States
Peking Union Medical College Hospital

Recruiting

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France; Advanced Accelerator Applications

Recruiting

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM)

Pancreatic Neuroendocrine Carcinoma

France
H. Lundbeck A/S

Completed

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

Schizophrenia

United States
Sinotau Pharmaceutical Group

Recruiting

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Neuroendocrine Tumors

China
Gilead Sciences

Completed

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension (Darusentan)

Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Denmark, France, Germany, New Zealand
Dana-Farber Cancer Institute
Novartis

Not yet recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Grupo Espanol de Tumores Neuroendocrinos
MFAR; ITM Oncologics GmbH

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL)

Thymus Neoplasms | Neuroendocrine Tumors | Lung Neuroendocrine Neoplasm

Spain, Italy, France
Melanoma and Skin Cancer Trials Limited

Recruiting

Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM)

Metastatic Merkel Cell Carcinoma

Australia
H. Lundbeck A/S

Completed

Safety and Efficacy of Zicronapine in Patients With Schizophrenia

Schizophrenia

Czech Republic, Estonia, Finland, France, Poland
Novartis Pharmaceuticals

Recruiting

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Breast Cancer

France, Germany, Spain, Portugal
H. Lundbeck A/S

Completed

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

Healthy

United States
OncoC4, Inc.
Prostate Cancer Clinical Trials Consortium

Recruiting

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (PRESERVE-006)

Metastatic Castration-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

Stage IV Uveal Melanoma AJCC v7 | Recurrent Uveal Melanoma

United States
H. Lundbeck A/S

Completed

Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer

Alzheimer Dementia (AD)

China
Georgetown University
Bristol-Myers Squibb; Advanced Accelerator Applications

Completed

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Small Cell Lung Cancer Extensive Stage

United States
H. Lundbeck A/S

Completed

Efficacy of Lu 31-130 in Patients With Schizophrenia

Schizophrenia

Philippines, Hong Kong, Czech Republic, France, Indonesia, Poland, Spain, Thailand
H. Lundbeck A/S

Completed

Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.

Healthy

United Kingdom
University Hospital, Bordeaux
Advanced Accelerator Applications

Recruiting

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (LUTARTERIAL)

Neuroendocrine Tumor | Liver Metastases | Neuroendocrine Gastroenteropancreatic Tumour

France
University of Warmia and Mazury
Stowarzyszenie Pacjentów i Osób Wspierających Chorych na Guzy Neuroendokrynne

Unknown

Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression (POLNETS_PRRT)

Neuroendocrine Tumors

Poland
H. Lundbeck A/S

Completed

Dose-finding Study With Lu AA24530 in Major Depressive Disorder

Major Depressive Disorder

Ukraine, Lithuania, France, Austria, Russian Federation, Australia, Belgium, Canada, Czech Republic, Finland, India, Korea, Republic of, Malaysia, Norway, Philippines, Serbia, Sweden
Jules Bordet Institute

Withdrawn

Randomized Phase III of PRRT Versus Interferon (CASTOR)

Gastro-intestinal Neuroendocrine Tumors

Belgium
University Hospital of Ferrara

Recruiting

Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) (FENET-2016)

Neuroendocrine Tumors | Peptide Receptor Radionuclide Therapy (PRRT)

Italy
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)

Gastro-enteropancreatic Neuroendocrine Tumor

Spain, United States, United Kingdom, France, Canada, Germany, Netherlands, Italy, Korea, Republic of
Takeda

Completed

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

Healthy Adult Participants

Japan
H. Lundbeck A/S

Completed

Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder

Chile, Argentina, Colombia, Costa Rica, Estonia, Finland, France, Hungary, Peru, Russian Federation, South Africa
Takeda

Completed

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

Major Depressive Disorder

Japan
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women

Healthy

China
H. Lundbeck A/S

Completed

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Depressive Disorder, Major

Spain, Hungary, Russian Federation, Bulgaria, Estonia, France, Germany, Italy, Latvia, Poland, Serbia, South Africa, United Kingdom
Takeda

Completed

A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
H. Lundbeck A/S

Completed

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (DayBreak)

Schizophrenia

Estonia, Mexico, Poland, Serbia, Ukraine, United States, Bulgaria, Canada, Czechia, Finland, Romania, Russian Federation, Slovakia, Spain
H. Lundbeck A/S

Completed

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

Cytochrome P450 Interaction

United Kingdom, United States
Otsuka Pharmaceutical Development & Commercialization...
PRA Health Sciences

Completed

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Schizophrenia | Bipolar I Disorder

United States
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes

Major Depressive Disorder
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
H. Lundbeck A/S

Terminated

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (Anew)

Treatment-resistant Schizophrenia

United States, Japan, Russian Federation, Bulgaria, United Kingdom
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
Laboratoires Thea

Completed

Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery

Cataract

France
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Takeda
H. Lundbeck A/S

Completed

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Takeda
H. Lundbeck A/S

Completed

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Major Depressive Disorder

France, Ukraine, Germany, Malaysia, South Africa, Korea, Republic of, Russian Federation, Czech Republic, Lithuania, United Kingdom, Latvia, Australia, Netherlands, Poland, Taiwan
Takeda
H. Lundbeck A/S

Completed

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Takeda

Completed

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Takeda

Completed

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Depressive Disorder, Major

Taiwan, Germany, Hong Kong, Poland, Malaysia, Romania, Serbia, Ukraine, Japan, Finland, Latvia, Croatia, India, Korea, Republic of, Philippines, Russian Federation
H. Lundbeck A/S

Completed

Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls

Depression

United Kingdom
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder

Search clinical trials for: Lu AA34893

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations